Kuchel O, Shigetomi S
Clinical Research Institute of Montreal, Hôtel-Dieu Hospital, University of Montreal, Canada.
Hypertens Res. 1995 Jun;18 Suppl 1:S183-5. doi: 10.1291/hypres.18.supplementi_s183.
Baseline dihydroxyphenylalanine (DOPA) and dopamine (DA), their respective sulfates as well as oral DOPA administration-induced changes were compared in age- and blood pressure-matched hypertensive patients without and with moderate chronic renal failure (CRF) and control subjects. The only common feature of both hypertensive groups was a defective DA generation from DOPA. Hypertensive patients with moderate CRF were distinct from those without, having increased basal concentrations of plasma DOPA and DA sulfates. After oral DOPA administration, plasma and urinary DOPA sulfate rose while renal DA sulfate clearance was decreased. Possible enzymatic defects contributing to CRF-induced increases of DOPA and DA sulfates and their potential role in perpetuating renal failure via glomerular hypertension are discussed.
在年龄和血压匹配的无中度慢性肾衰竭(CRF)和有中度慢性肾衰竭的高血压患者以及对照受试者中,比较了基线二羟基苯丙氨酸(DOPA)和多巴胺(DA)、它们各自的硫酸盐以及口服DOPA给药引起的变化。两个高血压组的唯一共同特征是从DOPA生成DA存在缺陷。有中度CRF的高血压患者与无CRF的患者不同,其血浆DOPA和DA硫酸盐的基础浓度升高。口服DOPA给药后,血浆和尿中DOPA硫酸盐升高,而肾DA硫酸盐清除率降低。讨论了可能导致CRF引起的DOPA和DA硫酸盐增加的酶缺陷及其通过肾小球高血压使肾衰竭持续存在的潜在作用。